Tofacitinib for refractory uveitis and scleritis

PURPOSE: To report the successful use of tofacitinib in the treatment of refractory uveitis and scleritis. OBSERVATIONS: Two patients, one with scleritis and another with anterior and intermediate uveitis, presented with refractory disease after failure of multiple steroid-sparing therapies. Treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Paley, Michael A., Karacal, Humeyra, Rao, P. Kumar, Margolis, Todd P., Miner, Jonathan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Case report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288302/
https://www.ncbi.nlm.nih.gov/pubmed/30582071
http://dx.doi.org/10.1016/j.ajoc.2018.12.001
_version_ 1783379771973959680
author Paley, Michael A.
Karacal, Humeyra
Rao, P. Kumar
Margolis, Todd P.
Miner, Jonathan J.
author_facet Paley, Michael A.
Karacal, Humeyra
Rao, P. Kumar
Margolis, Todd P.
Miner, Jonathan J.
author_sort Paley, Michael A.
collection PubMed
description PURPOSE: To report the successful use of tofacitinib in the treatment of refractory uveitis and scleritis. OBSERVATIONS: Two patients, one with scleritis and another with anterior and intermediate uveitis, presented with refractory disease after failure of multiple steroid-sparing therapies. Treatment with tofacitinib led to durable resolution of uveitis and scleritis. CONCLUSIONS AND IMPORTANCE: Tofacitinib is a potential novel treatment option for refractory, noninfectious inflammatory eye disease.
format Online
Article
Text
id pubmed-6288302
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-62883022018-12-21 Tofacitinib for refractory uveitis and scleritis Paley, Michael A. Karacal, Humeyra Rao, P. Kumar Margolis, Todd P. Miner, Jonathan J. Am J Ophthalmol Case Rep Case report PURPOSE: To report the successful use of tofacitinib in the treatment of refractory uveitis and scleritis. OBSERVATIONS: Two patients, one with scleritis and another with anterior and intermediate uveitis, presented with refractory disease after failure of multiple steroid-sparing therapies. Treatment with tofacitinib led to durable resolution of uveitis and scleritis. CONCLUSIONS AND IMPORTANCE: Tofacitinib is a potential novel treatment option for refractory, noninfectious inflammatory eye disease. Elsevier 2018-12-04 /pmc/articles/PMC6288302/ /pubmed/30582071 http://dx.doi.org/10.1016/j.ajoc.2018.12.001 Text en © 2018 The Authors. Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case report
Paley, Michael A.
Karacal, Humeyra
Rao, P. Kumar
Margolis, Todd P.
Miner, Jonathan J.
Tofacitinib for refractory uveitis and scleritis
title Tofacitinib for refractory uveitis and scleritis
title_full Tofacitinib for refractory uveitis and scleritis
title_fullStr Tofacitinib for refractory uveitis and scleritis
title_full_unstemmed Tofacitinib for refractory uveitis and scleritis
title_short Tofacitinib for refractory uveitis and scleritis
title_sort tofacitinib for refractory uveitis and scleritis
topic Case report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288302/
https://www.ncbi.nlm.nih.gov/pubmed/30582071
http://dx.doi.org/10.1016/j.ajoc.2018.12.001
work_keys_str_mv AT paleymichaela tofacitinibforrefractoryuveitisandscleritis
AT karacalhumeyra tofacitinibforrefractoryuveitisandscleritis
AT raopkumar tofacitinibforrefractoryuveitisandscleritis
AT margolistoddp tofacitinibforrefractoryuveitisandscleritis
AT minerjonathanj tofacitinibforrefractoryuveitisandscleritis

Ejemplares similares